Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs)
Author(s) -
Juwon Yim,
Jordan R. Smith,
Nivedita B. Singh,
Seth Rice,
Kyle Stamper,
Cristina García de la Mària,
Arnold S. Bayer,
Nagendra N. Mishra,
José M. Miró,
Truc T. Tran,
César A. Arias,
Paul M. Sullam,
Michael J. Rybak
Publication year - 2017
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkx130
Subject(s) - daptomycin , streptococcus mitis , gentamicin , ceftriaxone , microbiology and biotechnology , antibiotics , penicillin , endocarditis , cephalosporin , streptococcus , medicine , pharmacology , vancomycin , biology , bacteria , staphylococcus aureus , genetics
Among viridans group streptococcal infective endocarditis (IE), the Streptococcus mitis group is the most common aetiological organism. Treatment of IE caused by the S. mitis group is challenging due to the high frequency of β-lactam resistance, drug allergy and intolerability of mainstay antimicrobial agents such as vancomycin or gentamicin. Daptomycin has been suggested as an alternative therapeutic option in these scenarios based on its excellent susceptibility profile against S. mitis group strains . However, the propensity of many S. mitis group strains to rapidly evolve stable, high-level daptomycin resistance potentially limits this approach.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom